Current analyses of the pioneer among the JAK-i

The first representative of the Janus kinase (JAK) inhibitor class to be approved for atopic dermatitis was baricitinib. In an extensive study program, this selective and reversible inhibitor of JAK-1 and JAK-2 has demonstrated rapid relief of itching and skin lesions – even in areas of the body that are often difficult to treat. Real-world data is now available that confirms this positive balance.